Indicators on Clinical trial recruitment for ABBV-744 study You Should Know
In Section C, contributors will obtain ABBV-744 and oral navitoclax. In Phase D, individuals will get ABBV-744 and ruxolitinib. Participants will obtain treatment until eventually ailment progression or the individuals are unable to tolerate the study drugs.88 These preclinical studies offer paradigms for foreseeable future clinical trials in AML,